Next-Gen Collagen Biostimulators Compared: Which One Can Be Removed If It Goes Wrong?

Two kinds of people ask me how to choose a collagen biostimulator. The first hasn't had anything injected yet—they arrive with a comparison chart the clinic handed them and ask, "What's the real difference between Sculptra, AestheFill and Ellansé, and which one is better?" The second has already been injected, can feel a few hard lumps on the face, went back to the original clinic and was told "it's rare, just massage it," and eventually found their way to me.

These two people actually need the same answer—they're just standing at opposite ends of the timeline. So in this piece I want to compare from a different angle. Not "which lasts longer, which looks most natural"—that kind of table is all over the internet. What I want to show you is the axis most comparison articles skip: if it forms a lump on your face, can this material be taken out?

This is the reality a filler-revision physician deals with every day. They're all called "collagen biostimulators," but some can be half-dissolved, some can't be dissolved at all, and some can't even be touched by an enzyme and have to be handled physically. When you're deciding whether to get injected, hardly anyone tells you this side of the story.

First, sort them out: these "collagen biostimulators" aren't the same thing at all

People are used to lumping this whole category together as "collagen shots" or "biostimulators," as if they were one family with different brand names. In reality their ingredients differ a great deal, and the ingredient is what decides how a problem gets handled. I sort the seven common products on the market into three groups, organized by the logic of "can it be taken out?"

Group 1: hyaluronic acid plus microspheres, the "hybrids"—semi-reversible

These are the newest batch, and one of the main subjects of this article. They mix collagen-stimulating microspheres into a base of HA (hyaluronic acid), so a single injection gives you both immediate plumpness and later collagen growth.

• HArmonyCa (crosslinked HA plus CaHA microspheres, by Allergan; approved in Taiwan under the name 恆緹佳, also called 媄神針). A hybrid of crosslinked hyaluronic acid and CaHA (calcium hydroxylapatite) microspheres.
• Juvelook (PDLLA plus HA, by VAIM of Korea; known in Taiwan as 新童妍針). PDLLA (poly-D,L-lactic acid) microspheres combined with hyaluronic acid.
• Lenisna (Juvelook Volume, the larger-particle version). The high-molecular version of Juvelook, also from VAIM of Korea—same PDLLA-plus-HA logic, just with larger microspheres and a higher concentration, aimed at deep volumizing. Its status in Taiwan is a special case, and there's a whole section on it below.

The keyword for this group is semi-reversible: the HA half can be dissolved with hyaluronidase (the enzyme used medically to address residual HA filler, and only after an in-person physician assessment), but the microsphere half cannot.

Group 2: pure microsphere stimulators—not enzyme-dissolvable

These are the more familiar "classic three." They contain no hyaluronic acid—they're just high-molecular-weight microspheres that the body slowly metabolizes, injected so that your own tissue reaction to the microspheres grows your own collagen.

• Sculptra (PLLA). PLLA (poly-L-lactic acid), which gradually stimulates deep collagen for whole-face contour support.
• Ellansé (PCL; known in Taiwan as 洢蓮絲, sometimes written 依戀詩). PCL (polycaprolactone), a dual mechanism of immediate fill plus long-lasting collagen, with strong support and longer duration.
• AestheFill (PDLLA). Also PDLLA, softer in texture with even particles, leaning more toward skin quality.

Nothing in this group can be dissolved by an enzyme. They aren't hyaluronic acid, so hyaluronidase has no effect on them.

Group 3: pure CaHA—mechanical or surgical only

• Radiesse (CaHA; known in Taiwan as 微晶瓷, also called 再生針). Pure CaHA, which gives immediate lift right after injection and is often used on the nose or chin where you want definition.

It, too, can't be dissolved with hyaluronidase. Dealing with CaHA deposits means mechanical dispersion or physical extraction, not chemical dissolution.

Key point: The tables you find when you search "collagen filler comparison" almost all compare "effect, duration, recovery time." But what really matters to you about these three groups is the last column nobody writes down—reversibility. Hyaluronic acid is always the exception: it's the only one that dissolves. For every other material, once there's a problem, the handling logic is completely different.

Seven products at a glance: ingredient, instant plumpness, reversibility, nodule type

Putting everything above back together makes it much clearer. I've deliberately placed "reversibility" in the most important position in this table—because it's the column you're least likely to be told about elsewhere, yet the one that matters most when something goes wrong.

In a retrospective study of more than 1,100 PCL (Ellansé) treatments, the authors put it bluntly: PCL-based fillers "cannot be immediately removed by injecting an enzyme." That same study also honestly shows that its overall complication rate is in fact very low—and these two facts have to be read together: a low chance of forming a lump does not mean it will be easy to deal with if one forms. That is exactly the value of the reversibility axis.

Why "hyaluronidase to the rescue" doesn't work for most biostimulators

A lot of people's sense of safety about fillers comes from one impression: "If it goes wrong, you can just dissolve it." That impression is only true for hyaluronic acid.

Hyaluronidase is an enzyme that specifically breaks down hyaluronic acid. It recognizes only that molecule; every other material is invisible to it. So:

• Pure microsphere stimulators (Sculptra, Ellansé, AestheFill): there's no hyaluronic acid inside, so injecting hyaluronidase is like injecting saline—the microspheres and the collagen they've stimulated don't budge.
• CaHA (Radiesse): also not hyaluronic acid. Handling CaHA deposits follows a stepwise clinical path—observe the asymptomatic ones first, then use mechanical measures like massage and saline dispersion, then medication or laser if that's not enough, and only at the end, extraction or surgery. Nowhere on that ladder is there a "dissolve it with hyaluronidase" step, because it simply can't be dissolved.
• Hybrids (HArmonyCa, Juvelook, Lenisna): this is the one most easily misunderstood. You'd think, "There's hyaluronic acid in it, so surely it dissolves"—yes, but only the HA half dissolves. This is why someone often comes back after a hyaluronidase injection reporting that the lump "shrank a little, then grew back": what shrank was the dissolved HA volume, while the microspheres or CaHA that were actually holding it up and actually driving the inflammation are still right there.

Key point: The "semi-reversible" nature of hybrids sounds like an advantage—as if you can at least dissolve half. But from a revision standpoint it's actually a hidden cost. Because once the HA half is dissolved, the remaining problems (the microsphere core, the delayed inflammation) become harder to identify and easier to misjudge as "already dealt with."

When nodules appear, and what they look like

"I was completely fine right after the injection—why did a lump show up months later?" This is one of the most common confusions I hear in clinic. Biostimulator nodules have their own timeline, and more than one form.

The rough timeline:

• Within the first few days: mostly normal swelling and bruising, which resolves on its own—usually not a nodule.
• Around three weeks: you start to feel non-inflammatory hard nodules, often from injection that was too superficial, uneven distribution, or local stacking of microspheres. There's a reported case of PDLLA (like Juvelook) placed in the tear trough where a nodule appeared about three weeks after injection.
• Three months to several years: this is the stretch to watch. Delayed hypersensitivity or granulomatous reactions can take a long time to appear—PLLA (Sculptra) has cases of foreign-body granuloma forming years after injection; PCL (Ellansé) has a report of a granuloma erupting nine months after injection that required a year of medication to fully resolve. With that much time in between, many people never connect the lump to that original injection.

Two forms, handled differently:

One is the physical, stacked type: it feels like discrete beads, sits in a fixed spot, isn't especially red or painful—the material is simply lodged there. This type usually responds well to ultrasound-guided minimally invasive extraction.

The other is the delayed immune type: I've seen more of it in clinic over the last few years, and it's the most tormenting kind. It shows up as recurrent swelling in the same spot; for some people it flares every two or three days, and in severe cases swells so much the eye won't open, needing a return visit for anti-inflammatory medication and antibiotics to bring it down. In the literature, this kind of delayed, recurrent inflammation is linked to biofilm (a thin film of bacteria attached to the filler)—an analysis of more than sixty patients with delayed filler complications found that biofilm is an important risk factor for delayed nodules and chronic inflammation, with cultures growing organisms such as Staphylococcus aureus.

As for the overall risk of hybrids, take HArmonyCa as an example: a retrospective analysis covering more than four hundred participants showed the rate of nodules at the implant site was about 1.2%, with most adverse reactions mild—so the odds really aren't high. But you already know what I'm going to say: low odds don't mean it's easy to take out if it does happen.

Key point: What really wears people down with the delayed immune type is usually not the appearance but the daily life. The thing people with recurrent swelling say to me most often is, "Every time I go out, someone asks what happened to me," and over time many stop wanting to go out at all, their mood sinking with it. That burden is something no "lasts X months" comparison table can measure.

Lenisna (Juvelook Volume): not yet widespread—understand what it is first

I'm pulling Lenisna out for its own section because it currently sits in a position that's easy to be misled about.

It's actually the large-molecule version of Juvelook, called Juvelook Volume by the manufacturer, likewise from VAIM of Korea. The difference is its higher PDLLA concentration and larger microspheres, designed to be placed deeper and to restore larger volume. The ingredient logic is the same as Juvelook—a hybrid of PDLLA microspheres plus hyaluronic acid—so its reversibility is also the same, semi-reversible: the hyaluronic acid dissolves, the PDLLA does not.

The crux is its approval status in Taiwan. Standard Juvelook already has Taiwan approval (Taiwan medical device license 037021). But for Lenisna, the large-molecule version, I can't find a separate Taiwan license. The two differ in concentration, microsphere size and intended use—they're different products, and Juvelook clearing approval does not mean Lenisna is automatically within the legal scope. Lenisna is already in use in markets such as Korea and Japan (where it's called Jubeck Volume), but that isn't the same as being legally on the market in Taiwan.

I'm writing this not to frighten you, but because it's being pushed ahead of itself by marketing. If someone introduces you to "the new large-molecule Juvelook" or an "upgraded Juvelook," you should at least know two things: first, it's a PDLLA hybrid, so if there's a problem it's still only semi-reversible; and second, ask clearly whether what you're getting is the approved Juvelook or the not-separately-licensed Lenisna. A product this newly launched, with still-thin real-world long-term data, deserves an extra measure of caution.

If a nodule does form: the decision ladder from observation to ultrasound-guided extraction

Suppose a lump has already appeared. Whichever product you had, the approach is a ladder, not extraction straight off the bat.

1. Identify the material first. This is the first step and the one most easily gotten wrong. You have to establish whether what was injected was hyaluronic acid, a hybrid, or pure microspheres—hyaluronidase is only useful for hyaluronic acid and the HA half of a hybrid. Get the material wrong and the whole revision plan is wrong.
2. If it's asymptomatic, observe first. A small nodule that isn't red, painful, growing, or affecting appearance often doesn't need to be rushed into more injections or into extraction. Over-treating can sometimes be more trouble than leaving it be.
3. For the inflammatory type, control the inflammation first. For recurrent swelling suspicious for biofilm, first bring the inflammation and infection down (medication)—this handles the "current symptom." But understand that medication suppresses the symptom; it doesn't remove the foreign material. That's why so many people find "the medication helps, then it swells again once I stop."
4. Energy devices offer a chance for some materials. For microspheres like PDLLA, there's a case report of monopolar radiofrequency resolving a non-inflammatory tear-trough nodule within a short period. It's one option, but it doesn't apply to every material or every form.
5. Physical extraction is only after conservative measures have run their course. When none of the above resolves it, or the lump is itself a solid buildup of material, then you move to extraction. What I do is locate the material under ultrasound guidance (ultrasound-guided)—first getting a clear view of the nodule, vessels and nerves, then physically extracting or debulking the material through a single pinhole one to two millimeters wide, rather than blindly aspirating or scraping.

The goal for the delayed immune type has to be stated honestly: after ultrasound-guided localization and aspirating out most of the deposit, there may still be occasional swelling, but the frequency and severity of flares will be markedly lower than before extraction, and most people get substantial relief. I won't tell you "one-time cure, never recurs," because that isn't the truth; but removing most of the foreign material really does come closer to genuinely solving the problem than repeatedly injecting hyaluronidase or continually suppressing symptoms with steroids.

This is also why I keep emphasizing that you can only handle something safely once you can see it. These next-gen materials are increasingly hybrids, increasingly hard to judge by palpation alone, and here ultrasound isn't a bonus—it's a necessity. For the full approach to filler nodules and their capsule extraction, you can read on in the filler removal and revision services page, and the dedicated condition page for collagen-stimulator nodules.

How a revision physician would think about "which one to choose" for you

Back to that person at the start holding the comparison chart. If you ask me "which one is the safest," my answer will disappoint you a little: there is no single safest one.

Safety is half about the material and half about who injects it, at what depth, in what amount, along with your own constitution and history. The same material, placed at the right depth with restrained dosing, can be very safe; injected too shallow, too much, too superficially, even the gentlest material can cause problems. So if you compare "which one to choose" only on "effect," you'll miss the most important half.

From a revision standpoint, I'd suggest you rephrase the question: if it forms something on my face that can't be taken out, which kind can I live with?

• If you care a lot about "at least having a way back," then hyaluronic acid (the only one that dissolves) and hybrids (at least the half that dissolves) will feel psychologically reassuring—but be clear that the remaining half of a hybrid can't be dissolved.
• If you have a history of recurrent filler inflammation, delayed swelling, or an allergy-prone constitution, I'd ask you to assess any irreversible pure-microsphere material far more carefully, because once there's a problem, you have no dissolving route out.
• Whichever you choose, finding a physician who is both able and willing to help you if something goes wrong matters more than the material itself. Plenty of people can inject; relatively few can clean up afterward.

This is also why we put our focus on filler removal and revision rather than pushing injections. You can follow the funnel through a couple more pieces: to understand the mechanisms and risks of each material, read the mechanisms and risks of collagen biostimulators; if you've had HArmonyCa and are worried, read what to do about HArmonyCa nodules; for Juvelook and Lenisna, read handling Juvelook and Lenisna nodules; for AestheFill, see the AestheFill nodule treatment ladder; for Ellansé, read Ellansé delayed-onset nodules.

If you already have a palpable lump and aren't sure which product was injected, this is exactly the situation best served by an ultrasound assessment first, to see the material and its location clearly. To discuss further, you're welcome to reach Dr. Ta-Ju Liu's team through the consultation booking page.

Frequently asked questions

Can biostimulator nodules be dissolved like hyaluronic acid?

Only the hyaluronic acid portion can. Pure microsphere stimulators (Sculptra, Ellansé, AestheFill) and CaHA (Radiesse) can't be dissolved by any enzyme. For hybrids (HArmonyCa, Juvelook, Lenisna), a hyaluronidase injection only dissolves the HA half; the microspheres stay in place, which is why it commonly "shrinks a little, then comes back."

Are "hybrids" like HArmonyCa and Juvelook safer?

They add hyaluronic acid, a dissolvable component, so the sense of having a way back is indeed a bit better, and short-term studies show a low nodule rate. But remember that the microsphere half—the part that actually does the collagen stimulation and can actually trigger inflammation—can't be dissolved. "Semi-reversible" is both an advantage and a hidden cost; don't let your guard down just because "at least half dissolves."

Is Lenisna available in Taiwan? Is it the same as Juvelook?

Lenisna is the large-molecule version of Juvelook (Juvelook Volume), and its ingredient logic is the same—PDLLA plus hyaluronic acid. Standard Juvelook already has Taiwan approval, but for the Lenisna large-molecule version there's currently no separate Taiwan license to be found. If someone introduces you to an "upgraded version," be sure to confirm whether what you're getting is the approved Juvelook or the not-separately-licensed Lenisna.

I've already had it done—could a lump appear months later?

It's possible. The nodule timeline for biostimulators is wide: those around three weeks are mostly physical hard nodules, while those appearing from three months to several years lean toward delayed hypersensitivity or granuloma. After a long interval it's easy to forget the connection to that original injection. If you notice recurrent swelling, steady enlargement, or redness and pain, I'd recommend a return visit for assessment rather than dismissing it as ordinary swelling.

How do I lower the chance of a lump before getting injected?

Beyond material choice, the injection depth and dose, the injector's technique, and the cleanliness of the instruments and environment (to reduce biofilm risk) all matter greatly. Honestly disclosing your past filler history and allergy history beforehand, so the physician can assess whether an irreversible material suits you, matters far more than trying to fix things afterward.

Is there any biostimulator that's simply the safest?

No. Safety is half in the material and half in who injects it and your own constitution. Rather than asking "which is safest," the more practical question is "if it forms a lump I can't remove, which kind can I live with?" A small, symptom-free nodule doesn't need to be rushed into treatment; physical extraction is what you reach for when conservative measures have run their course, not the first step.

References

1. Lin F-Y, Christen M-O. Polycaprolactone-based dermal filler complications: A retrospective study of 1111 treatments. J Cosmet Dermatol. 2020;19(8):1907-1911. PMID: 32485052.
2. Seo Y, et al. Energy-Based Device Management of Nodular Reaction Following Poly-D,L-Lactic Acid Injection for Tear Trough Rejuvenation. J Cosmet Dermatol. 2025. PMID: 39283001.
3. Ledon JA, et al. Late-onset granuloma formation after poly-L-lactic acid injection. JAAD Case Rep. 2016. PMID: 27051828.
4. Ragonez F, et al. Eruptive granuloma after injection of Ellansé® successfully treated using methotrexate. Ann Dermatol Venereol. 2020;147(8-9):525-529. PMID: 32276735.
5. Munia MA, et al. A Structured Approach for Treating Calcium Hydroxylapatite Focal Accumulations. Aesthet Surg J. 2024. PMID: 38366791.
6. A Retrospective Analysis of Safety in Participants Treated with a Hybrid Hyaluronic Acid and Calcium Hydroxyapatite Filler. Plast Reconstr Surg Glob Open. 2024. PMID: 38348461.
7. Biofilm formation is a risk factor for late and delayed complications of filler injection. Front Microbiol. 2024;15. PMID: 38260874.

Content review statement: This article was written by Dr. Ta-Ju Liu based on clinical experience and current literature, offered as health education and not a substitute for in-person care. The specifics, indications and management of any material still require individualized judgment after an in-person consultation and imaging assessment by a physician.